Results for: Pneumococcal Vaccine

The Nasdaq Composite fell by approximately 2% on Tuesday, with Vaxcyte, Inc. (PCVX) leading the gainers after positive Phase 1/2 trial results for its pneumococcal conjugate vaccine candidate. Other notable stock movers included Sable Offshore, Shoals Technologies, Polestar Automotive, Big Tree Cloud, Applied Optoelectronics, Unity Software, BridgeBio Pharma, Montana Technologies, Intchains Group, Keros Therapeutics, XPeng, Vera Therapeutics, Novavax, Bilibili, and The J. M. Smucker Company.

Vaxcyte, Inc. (PCVX) announced positive results from its Phase 1/2 trial for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate. The vaccine demonstrated robust immune responses and a favorable safety profile, potentially positioning it as a competitive alternative to existing pneumococcal vaccines like Pfizer’s Prevnar 20.